167 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
22 Apr 24
Report of Foreign Private Issuer
8:02am
to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
16 Apr 24
Report of Foreign Private Issuer
8:00am
such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more … in respect of such commercial transaction is equal to or greater than $20 million.
Litigation
From time to time, the Company may be involved in various
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
7 Feb 24
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
8:02am
harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks
6-K
7bqves0ta3 br1
22 Jan 24
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
ft5u 3zj21s6y2
17 Jan 24
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
oo54pjlrwxuc6 una
20 Dec 23
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
8:01am
6-K
EX-99.2
klt m4poscx2mpsf
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
6-K
mlsrwhgppu7wlcxcdk
7 Nov 23
Report of Foreign Private Issuer
4:30pm
6-K
jwz8xpbhf 46wg1
18 Sep 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
d7v rndbf6u
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
6-K
EX-99.2
oblb4de6o wd3bf
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
si3tac5x
2 Aug 23
Report of Foreign Private Issuer
8:05am
6-K
EX-99.1
lijlsu w0g
31 Jul 23
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
8:05am
6-K
EX-99.1
8qj33hq7gf91j
26 Jun 23
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
8:03am
6-K
EX-99.2
fs7hw 9yu49mx84
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
lgks03ovnr clh4yq
31 May 23
Report of Foreign Private Issuer
8:09am
6-K
EX-99.1
2aivboqoct7rf1bn
8 May 23
Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to
8:02am
6-K
EX-99.1
v8f62z7mv3zip84tm
19 Apr 23
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy
8:03am